Industries - Asthma Therapeutics Market Analysis by Drug Class (Bronchodilators, Anti-inflammatory, Combination Therapy), by Device Type (Dry Powder, Inhalers, Soft Mist, Metered Dose, Nebulizers), by Route of Administration (Inhaled, Oral, Intravenous), and by Region – Forecast to 2025

Ablation Technology Market Analysis

Asthma Therapeutics Market Analysis by Drug Class (Bronchodilators, Anti-inflammatory, Combination Therapy), by Device Type (Dry Powder, Inhalers, Soft Mist, Metered Dose, Nebulizers), by Route of Administration (Inhaled, Oral, Intravenous), and by Region – Forecast to 2025
October 2020

SKU: N/A Category:
Clear
  • Description
  • Additional information
  • Enquire about

Description

Asthma Therapeutics Market Analysis by Drug Class (Bronchodilators, Anti-inflammatory, Combination Therapy), by Device Type (Dry Powder, Inhalers, Soft Mist, Metered Dose, Nebulizers), by Route of Administration (Inhaled, Oral, Intravenous), and by Region - Forecast to 2025

Published: October 2020 | Historical Data: 2017-2019 | Base Year: 2019
SKU: ICI-HC-1027 | Number of Pages: 135 | Category: Pharmaceuticals

The global asthma therapeutics market size is estimated to be USD 21.94 billion in 2019 and is expected to witness a CAGR of 3.2% during the forecast period. Rising prevalence of respiratory diseases, increasing demand for advanced therapeutics, and high investment in R&D are some of the major factors driving the market growth. In addition, the increasing number of respiratory disease-causing agents such as pollution, dust, and allergens, unhealthy lifestyles, and tobacco smoking habits among a large population are expected to boost the demand for these drugs in near future. However, patent expiry of the major drugs and intense competition among vendors hinder the market growth.

Asthma Therapeutics Market

By Drug Class

Based on drug class, the market is segmented into bronchodilators, anti-inflammatory, and combination therapy. In 2019, the combination therapy segment accounted for the largest revenue share owing to its high efficacy, availability, and adoption by patients. The anti-inflammatory drugs segment is projected to grow at a lucrative CAGR during the forecast period. This is attributed to the presence of promising drug molecules such as lebrikizumab and duplimab in pipeline.

By Device Type

Based on device type, the market is categorized into inhalers and nebulizers. Inhalers segment is further classified into metered dose, dry powder, and soft mist. Metered dose inhalers accounted for highest revenue share in 2019 in inhalers market. Inhalers are easy to operate, portable, effective, affordable, and reliable; thus its adoption is growing in developed as well as developing countries. Nebulizer segment is expected to grow at a steady CAGR during the forecast period owing to its increasing adoption in hospitals.

By Route of Administration

Based on route of administration, the market is divided into oral, inhaled, and others. The inhaled segment was the highest revenue-grossing segment in 2019 as it has a greater market penetration coupled with high compliance with the treatment regime of the patients. The oral segment is projected to grow at a significant CAGR during the forecast period owing to increasing incidence of respiratory diseases worldwide.

Regional Insights

In 2019, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the increasing adoption of inhaled therapies, rising number of patients suffering with asthma, and growing healthcare expenditure by the government. Asia Pacific is projected to exhibit the fastest CAGR over the forecast period owing to the rising prevalence of respiratory diseases, mounting demand for affordable treatment for respiratory diseases, growing geriatric population, and escalating awareness for inhaler’s use in this region.

North America Asthma Therapeutics Market Size (2017-2025), USD Billion

North America Asthma Therapeutics Market

Competitor Insights

Some of the major players in the asthma therapeutics market are AstraZeneca Plc (UK), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc (UK), Philips Healthcare (Netherlands), Roche Diagnostics (Switzerland), Sunovion Pharmaceuticals, Inc. (U.S.), Sanofi-Aventis (France), CareFusion Corporation (U.S.), Boehringer Ingelheim GmbH (Germany), and Merck & Co., Inc. (U.S.). Leading players operating in the asthma therapeutics industry are adopting various strategies including R&D investment, product launches, collaborations, mergers & acquisition, and regional expansions.

 

This exhaustive research report focuses on market size and forecast at global, segmental, regional, and country level along with key market trends and dynamics from 2017 to 2025. The asthma therapeutics market report is categorized into the following segments and subsegments:

Asthma Therapeutics Market, By Drug Class (Revenue, USD Billion, 2017 – 2025)

  • Bronchodilators
  • Anti-inflammatory
  • Combination therapy

Asthma Therapeutics Market, By Device Type (Revenue, USD Billion, 2017 – 2025)

  • Inhalers
    • Metered-dose inhalers
    • Dry powder inhalers
    • Soft mist inhalers
  • Nebulizers

Asthma Therapeutics Market, By Route of Administration (Revenue, USD Billion, 2017 – 2025)

  • Inhaled
  • Oral
  • Others

Asthma Therapeutics Market, By Region (Revenue, USD Billion, 2017 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Scope of Asthma Therapeutics Market Report:

Key Parameters Details
Data Availability 2017-2025
Historical Years 2017-2019
Base Year Considered 2019
Forecast Period 2019-2025
Company Profiles 10
Companies Considered (Across Value Chain) >40
Value Units Value in USD and CAGR in %
Market Segments Drug Class, Device Type, and Route of Administration,
Regional Coverage North America (U.S. and Canada), Europe (Germany, France, UK, Spain, Italy, Russia, and the Rest of Europe), Asia Pacific (China, Japan, Australia, India, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina and the Rest of LATAM), and the Middle East and Africa (South Africa, Saudi Arabia, Rest of MEA)
Key Market Players AstraZeneca Plc (UK), Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc (UK), Philips Healthcare (Netherlands), Roche Diagnostics (Switzerland), Sunovion Pharmaceuticals, Inc. (U.S.), Sanofi-Aventis (France), CareFusion Corporation (Beckton Dickinson and Co.) (U.S.), Boehringer Ingelheim GmbH (Germany), and Merck & Co., Inc. (U.S.).
Custom Analysis Customization up to 60 analyst hours

Asthma Therapeutics Market, By Drug Class (Revenue, USD Billion, 2017 – 2025)

  • Bronchodilators
  • Anti-inflammatory
  • Combination therapy

Asthma Therapeutics Market, By Device Type (Revenue, USD Billion, 2017 – 2025)

  • Inhalers
    • Metered-dose inhalers
    • Dry powder inhalers
    • Soft mist inhalers
  • Nebulizers

Asthma Therapeutics Market, By Route of Administration (Revenue, USD Billion, 2017 – 2025)

  • Inhaled
  • Oral
  • Others

Asthma Therapeutics Market, By Region (Revenue, USD Billion, 2017 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA
1. Research Methodology
 1.1. Research Objective
 1.2. Study Scope: Market Segments
 1.3. Study Timeframe, Limitations & Currency
 1.4. Domain-Assisted Cognition (DAC) Framework
  1.4.1. Three-stage Research Methodology
   1.4.1.1. Understand Ecosystem
    1.4.1.1.1. Secondary Research
    1.4.1.1.2. Primary Research
    1.4.1.1.3. Internal Repository
   1.4.1.2. Synthesize Information
    1.4.1.2.1. Data Analysis
    1.4.1.2.2. Data Triangulation
   1.4.1.3. Predict/Project Growth
    1.4.1.3.1. Market Size Estimation
     1.4.1.3.1.1. Bottom-up Approach
     1.4.1.3.1.2. Top-down Approach
    1.4.1.3.2. Data Validation
  1.4.2. Two-stage Quality Check Mechanism
   1.4.2.1. Inspection & Reporting
   1.4.2.2. Quality Audit
2. Market Summary
 2.1. Market Definition & Market Landscape
 2.2. Market Segment Snapshot
 2.3. Geographic Market Snapshot
3. Market Dynamics
 3.1. Market Driver Analysis
  3.1.1. Increasing incidences of asthma patients
  3.1.2. Increasing demand for novel drugs
  3.1.3. Increasing environmental concerns
  3.1.4. Growing government initiatives for creating air pollution awareness
 3.2. Market Restraint Analysis
  3.2.1. Patent expiry and extensive renewal process
  3.2.2. Stringent standardization protocols for novel drug approval
 3.3. Market Opportunities
  3.3.1. Growing emerging economies
  3.3.2. Increasing per capita spending on healthcare services
4. Industry Outlook
 4.1. Key Market Trends
 4.2. Value Chain Analysis
 4.3. Porter’s 5 Forces Analysis
 4.4. Pricing Analysis (2017-2019)
 4.5. Product Benchmarking
5. Covid-19 Impact and Deviation Analysis
 5.1. Covid-19 Prevalence Analysis
 5.2. Key Market Trends
 5.3. Market Size Deviation Analysis (2020-2025)
6. Asthma Therapeutics Market Size and Forecast, by Drug Class (2017-2025), USD Million
 6.1. Anti-inflammatory
 6.2. Bronchodilators
 6.3. Combination therapy
7. Asthma Therapeutics Market Size and Forecast, by Device Type (2017-2025), USD Million
 7.1. Inhalers
  7.1.1. Dry powder inhalers
  7.1.2. Metered-dose inhalers
  7.1.3. Soft mist inhalers
 7.2. Nebulizers
8. Asthma Therapeutics Market Size and Forecast, by Route of Administration (2017-2025), USD Million
 8.1. Oral
 8.2. Inhaled
 8.3. Others
9. Asthma Therapeutics Market, Regional Analysis (2017-2025), USD Million
 9.1. North America
  9.1.1. Introduction
   9.1.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.1.1.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.1.1.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
   9.1.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.1.2. U.S.
   9.1.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.1.2.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.1.2.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.1.3. Canada
   9.1.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.1.3.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.1.3.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
 9.2. Europe
  9.2.1. Introduction
   9.2.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.1.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.1.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
   9.2.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.2.2. Germany
   9.2.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.2.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.2.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.3. UK
   9.2.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.3.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.3.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.4. France
   9.2.4.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.4.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.4.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.5. Spain
   9.2.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.5.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.5.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.6. Italy
   9.2.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.6.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.6.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.7. Russia
   9.2.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.7.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.7.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.2.8. Rest of Europe
   9.2.8.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.2.8.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.2.8.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
 9.3. Asia Pacific (APAC)
  9.3.1. Introduction
   9.3.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.1.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.1.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
   9.3.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.3.2. China
   9.3.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.2.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.2.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.3.3. Japan
   9.3.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.3.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.3.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.3.4. India
   9.3.4.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.4.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.4.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.3.5. Australia
   9.3.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.5.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.5.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.3.6. South Korea
   9.3.6.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.6.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.6.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.3.7. Rest of Asia Pacific
   9.3.7.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.3.7.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.3.7.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
 9.4. Latin America (LATAM)
  9.4.1. Introduction
   9.4.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.1.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.4.1.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
   9.4.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.4.2. Brazil
   9.4.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.2.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.4.2.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.4.3. Mexico
   9.4.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.3.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.4.3.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.4.4. Argentina
   9.4.4.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.4.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.4.4.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.4.5. Rest of LATAM
   9.4.5.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.4.5.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.4.5.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
 9.5. Middle East & Africa (MEA)
  9.5.1. Introduction
   9.5.1.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.1.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.5.1.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
   9.5.1.4. Market Size & Forecast, by Country (2017-2025), USD Million
  9.5.2. South Africa
   9.5.2.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.2.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.5.2.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.5.3. Saudi Arabia
   9.5.3.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.3.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.5.3.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
  9.5.4. Rest of MEA
   9.5.4.1. Market Size & Forecast, by Drug Class (2017-2025), USD Million
   9.5.4.2. Market Size & Forecast, by Device Type (2017-2025), USD Million
   9.5.4.3. Market Size & Forecast, by Route of Administration (2017-2025), USD Million
10. Competitor Analysis
 10.1. Market Player Comparison
 10.2. Product-wise Player Mapping
 10.3. Region-wise Player Mapping
 10.4. Market Share Analysis
 10.5. Market Position Analysis
 10.6. Recent Development Analysis
11. Company Profiles
 11.1. AstraZeneca Plc (UK)
  11.1.1. Company Overview
  11.1.2. Company Financials
  11.1.3. Product Portfolio
  11.1.4. Recent Developments
 11.2. Teva Pharmaceutical Industries Ltd. (Israel)
  11.2.1. Company Overview
  11.2.2. Company Financials
  11.2.3. Product Portfolio
  11.2.4. Recent Developments
 11.3. GlaxoSmithKline Plc (UK)
  11.3.1. Company Overview
  11.3.2. Company Financials
  11.3.3. Product Portfolio
  11.3.4. Recent Developments
 11.4. Philips Healthcare (Netherlands)
  11.4.1. Company Overview
  11.4.2. Company Financials
  11.4.3. Product Portfolio
  11.4.4. Recent Developments
 11.5. Roche Diagnostics (Switzerland)
  11.5.1. Company Overview
  11.5.2. Company Financials
  11.5.3. Product Portfolio
  11.5.4. Recent Developments
 11.6. Sunovion Pharmaceuticals, Inc. (US)
  11.6.1. Company Overview
  11.6.2. Company Financials
  11.6.3. Product Portfolio
  11.6.4. Recent Developments
 11.7. Sanofi-Aventis (France)
  11.7.1. Company Overview
  11.7.2. Company Financials
  11.7.3. Product Portfolio
  11.7.4. Recent Developments
 11.8. CareFusion Corporation (Beckton Dickinson and Co.) (US)
  11.8.1. Company Overview
  11.8.2. Company Financials
  11.8.3. Product Portfolio
  11.8.4. Recent Developments
 11.9. Boehringer Ingelheim GmbH (Germany)
  11.9.1. Company Overview
  11.9.2. Company Financials
  11.9.3. Product Portfolio
  11.9.4. Recent Developments
 11.10. Merck & Co., Inc (US)
  11.10.1. Company Overview
  11.10.2. Company Financials
  11.10.3. Product Portfolio
  11.10.4. Recent Developments
(Note: Financials are captured for public listed companies)

Key questions addressed by the research report-

  1. What are the current market trends and future market forecast from 2019 to 2025 for Asthma Therapeutics market?
  2. What are the market dynamics and probable opportunities for market players during the forecast period?
  3. Initiatives undertaken my market players to address the COVID-19 impact to sustain in the competitive market.
  4. Which geographies have immense opportunities in different segments of the Asthma Therapeutics market?
  5. What are the recent strategies adopted by market players such as product launch, partnership, agreement, collaboration, merger & acquisition, and geographical expansion?


    Have any question? Check your free sample before purchase or connect with our expert.

    Additional information

    Licensing Types

    , , ,

    Enquire about Asthma Therapeutics Market Analysis by Drug Class (Bronchodilators, Anti-inflammatory, Combination Therapy), by Device Type (Dry Powder, Inhalers, Soft Mist, Metered Dose, Nebulizers), by Route of Administration (Inhaled, Oral, Intravenous), and by Region - Forecast to 2025